Dublin, Aug. 24, 2020 (GLOBE NEWSWIRE) -- The "Neuroendocrine Tumors - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Neuroendocrine Tumors Pipeline Insight, 2020" report provides comprehensive insights of the current clinical development scenario and growth prospects across the Neuroendocrine Tumors market. A detailed picture of the Neuroendocrine Tumors pipeline landscape is provided, which includes the disease overview and Neuroendocrine Tumors treatment guidelines. The assessment part of the report embraces in-depth Neuroendocrine Tumors commercial assessment and clinical assessment of the Neuroendocrine Tumors pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuroendocrine Tumors collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All the companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Neuroendocrine Tumors treatment.
- Neuroendocrine Tumors key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Neuroendocrine Tumors market.
In-depth Neuroendocrine Tumors Commercial Assessment Of Products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
Neuroendocrine Tumors Clinical Assessment Of Products
The report comprises comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Neuroendocrine Tumors report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neuroendocrine Tumors across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises detailed profiles of the Neuroendocrine Tumors therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Neuroendocrine Tumors research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Neuroendocrine Tumors .
Key Topics Covered:
1. Report Introduction
2. Neuroendocrine Tumors
3. Neuroendocrine Tumors Current Treatment Patterns
4. Neuroendocrine Tumors - Analytical Perspective
5. Therapeutic Assessment
6. Neuroendocrine Tumors Late Stage Products (Phase-III)
7. Neuroendocrine Tumors Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuroendocrine Tumors Discontinued Products
13. Neuroendocrine Tumors Product Profiles
14. Neuroendocrine Tumors Key Companies
15. Neuroendocrine Tumors Key Products
16. Dormant and Discontinued Products
17. Neuroendocrine Tumors Unmet Needs
18. Neuroendocrine Tumors Future Perspectives
19. Neuroendocrine Tumors Analyst Review
21. Report Methodology
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tus17k
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900